LUGPA 2014, Annual Meeting, November 6-8 / Chicago
LUGPA 2014
Annual Meeting
November 6-8 | Chicago
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.